Bacillary Dysentery (Shigellosis) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Bacillary Dysentery (Shigellosis) – Drugs In Development, 2024 report and make more profitable business decisions.
Shigella infection (shigellosis) is an intestinal disease caused by bacteria known as shigella. Symptoms include diarrhea, abdominal cramps, and fever. Predisposing factors include eating contaminated food, age, international travel, and being a homosexual man. Treatment includes antibiotics.
The Bacillary Dysentery (Shigellosis) drugs in development market research report provide comprehensive information on the therapeutics under development for Bacillary Dysentery (Shigellosis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bacillary Dysentery (Shigellosis) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Bacillary Dysentery (Shigellosis) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 28 molecules, with 20 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Bacillary Dysentery (Shigellosis) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Bacillary Dysentery (Shigellosis) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Bacillary Dysentery (Shigellosis) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Biocidium Biopharmaceuticals IncChongqing Zhifei Biological Products Co Ltd
Emergent BioSolutions Inc
EveliQure Biotechnologies GmbH
GSK plc
Hafion LLC
Hilleman Laboratories Pvt Ltd
Immuron Ltd
International Vaccine Institute
Intralytix Inc
Inventprise LLC
LimmaTech Biologics AG
Ostrich Pharma USA Inc
Pasteur Institute
PATH
PGTx Ltd
Protein Potential LLC
University of Kansas
University of Strathclyde
Vaxcyte Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Bacillary Dysentery (Shigellosis) reports